Among the major areas of care fixated by people is their health. As such, advances in medicines are duly welcome and highly appreciated. Progress in research of various diseases and development of drugs to help curb them is always a good indicator. One such aspect of progress has been noted in liposomal formulation.
The process of this formulation was discovered 50 years ago. It came about as a solution to a problem of drugs taken orally being exhausted and digested before reaching the intended target areas. The liposomal way was deemed best suited since it was a favorable carrier to both hydrophilic and hydrophobic drugs.
The simplicity of the liposomes' structural composition is key to its performance. They are made up of an aqueous solution which is engulfed in a strengthened mesh of either natural or synthetic phospholipids. The advantage of this is that it can fuse non-reactively with both hydrophilic and hydrophobic drugs, each attaching to the element it does not react to.
The main advantage of using liposomes comes from its core structure. The procedure of formation is key to this. They are formed when a specific heat level is exposed to phospholipids immersed in water. This provides the right atmosphere for formation of liposomes. The physiochemical composition should then be deduced so as to enable the liposome act as an appropriate carrier for an appropriate drug - given its composition to avoid any reactions.
Advances such as these have led to further progress in the medical field. The most famous being development of Doxorubicin, a form of anthracycline. This is a drug that was developed to curb the spread of cancer. It does this in two stages, first, by inserting base stains of DNA and RNA molecules which inhibits replication of cells. The second phase is inhibition of an enzyme known as topoisomerase II, which serves the same purpose of inhibition of cellular growth.
Further research and development on cancer and other terminal ailments have had positive results, and the outcomes lauded by the medical community as well as the general public. Research and testing of liposomes as anti- cancer drug carriers has brought about drugs which are n testing. These include doxorubicin, , lipoplatin, paclitaxel, aroplatin and cisplatin.
The study of liposomes has also led to development of vaccines and various other treatments. Various diseases and medical conditions which previously had no cure can now be vaccinated against. Such developments have established Epaxal, a vaccine against Hepatitis A, and Inflexal V, a vaccine against several types of influenza. A vaccine known as Stimuvax against lighter forms of cancer is in the offing.
Another point of progress thanks to this formulation has been in delivery of dietary supplements. It is still a new area under testing, but has great promise considering the level of success the formulations has garnered from targeted drug delivery. The process of the formulation is hence referred to as a new era of medical advances.
The process of this formulation was discovered 50 years ago. It came about as a solution to a problem of drugs taken orally being exhausted and digested before reaching the intended target areas. The liposomal way was deemed best suited since it was a favorable carrier to both hydrophilic and hydrophobic drugs.
The simplicity of the liposomes' structural composition is key to its performance. They are made up of an aqueous solution which is engulfed in a strengthened mesh of either natural or synthetic phospholipids. The advantage of this is that it can fuse non-reactively with both hydrophilic and hydrophobic drugs, each attaching to the element it does not react to.
The main advantage of using liposomes comes from its core structure. The procedure of formation is key to this. They are formed when a specific heat level is exposed to phospholipids immersed in water. This provides the right atmosphere for formation of liposomes. The physiochemical composition should then be deduced so as to enable the liposome act as an appropriate carrier for an appropriate drug - given its composition to avoid any reactions.
Advances such as these have led to further progress in the medical field. The most famous being development of Doxorubicin, a form of anthracycline. This is a drug that was developed to curb the spread of cancer. It does this in two stages, first, by inserting base stains of DNA and RNA molecules which inhibits replication of cells. The second phase is inhibition of an enzyme known as topoisomerase II, which serves the same purpose of inhibition of cellular growth.
Further research and development on cancer and other terminal ailments have had positive results, and the outcomes lauded by the medical community as well as the general public. Research and testing of liposomes as anti- cancer drug carriers has brought about drugs which are n testing. These include doxorubicin, , lipoplatin, paclitaxel, aroplatin and cisplatin.
The study of liposomes has also led to development of vaccines and various other treatments. Various diseases and medical conditions which previously had no cure can now be vaccinated against. Such developments have established Epaxal, a vaccine against Hepatitis A, and Inflexal V, a vaccine against several types of influenza. A vaccine known as Stimuvax against lighter forms of cancer is in the offing.
Another point of progress thanks to this formulation has been in delivery of dietary supplements. It is still a new area under testing, but has great promise considering the level of success the formulations has garnered from targeted drug delivery. The process of the formulation is hence referred to as a new era of medical advances.
No comments:
Post a Comment